Immunogenetic Association Underlying Severe COVID-19
- PMID: 33233531
- PMCID: PMC7711778
- DOI: 10.3390/vaccines8040700
Immunogenetic Association Underlying Severe COVID-19
Abstract
SARS-CoV2 has caused the current pandemic of new coronavirus disease 2019 (COVID-19) worldwide. Clinical outcomes of COVID-19 illness range broadly from asymptotic and mild to a life-threatening situation. This casts uncertainties for defining host determinants underlying the disease severity. Recent genetic analyses based on extensive clinical sample cohorts using genome-wide association studies (GWAS) and high throughput sequencing curation revealed genetic errors and gene loci associated with about 20% of life-threatening COVID-19 cases. Significantly, most of these critical genetic loci are enriched in two immune signaling pathways, i.e., interferon-mediated antiviral signaling and chemokine-mediated/inflammatory signaling. In line with these genetic profiling studies, the broad spectrum of COVID-19 illness could be explained by immuno-pathological regulation of these critical immunogenetic pathways through various epigenetic mechanisms, which further interconnect to other vital components such as those in the renin-angiotensin-aldosterone system (RAAS) because of its direct interaction with the virus causing COVID-19. Together, key genes unraveled by genetic profiling may provide targets for precisely early risk diagnosis and prophylactic design to relieve severe COVID-19. The confounding epigenetic mechanisms may be key to understanding the clinical broadness of COVID-19 illness.
Keywords: COVID-19; chemokine signaling; epigenetic regulation; genome-wide association; interferon signaling.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10. J Pathol. 2020. PMID: 32418199 Free PMC article. Review.
-
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.Clinics (Sao Paulo). 2021 Apr 9;76:e2342. doi: 10.6061/clinics/2021/e2342. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 33852652 Free PMC article. Review.
-
Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity.Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):515-524. doi: 10.1097/ACI.0000000000000786. Curr Opin Allergy Clin Immunol. 2021. PMID: 34494617 Review.
-
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.Trials. 2021 Feb 5;22(1):115. doi: 10.1186/s13063-021-05080-4. Trials. 2021. PMID: 33546734 Free PMC article.
-
Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation.Chem Biol Interact. 2022 Jan 5;351:109738. doi: 10.1016/j.cbi.2021.109738. Epub 2021 Nov 3. Chem Biol Interact. 2022. PMID: 34740598 Free PMC article. Review.
Cited by
-
The causal relationship between circulating cytokines and critically ill COVID-19: A bidirectional Mendelian randomization analysis.J Glob Health. 2022 Feb 19;12:05010. doi: 10.7189/jogh.12.05010. eCollection 2022. J Glob Health. 2022. PMID: 35356648 Free PMC article.
-
Dysregulated Interferon Response Underlying Severe COVID-19.Viruses. 2020 Dec 13;12(12):1433. doi: 10.3390/v12121433. Viruses. 2020. PMID: 33322160 Free PMC article. Review.
-
Functional Antibodies in COVID-19 Convalescent Plasma.medRxiv [Preprint]. 2021 Mar 11:2021.03.08.21253157. doi: 10.1101/2021.03.08.21253157. medRxiv. 2021. Update in: Nat Commun. 2021 Nov 25;12(1):6853. doi: 10.1038/s41467-021-27201-y. PMID: 33758875 Free PMC article. Updated. Preprint.
-
Immunometabolic Dysregulation at the Intersection of Obesity and COVID-19.Front Immunol. 2021 Oct 19;12:732913. doi: 10.3389/fimmu.2021.732913. eCollection 2021. Front Immunol. 2021. PMID: 34737743 Free PMC article. Review.
-
Therapeutic strategies to fight COVID-19: Which is the status artis?Br J Pharmacol. 2022 May;179(10):2128-2148. doi: 10.1111/bph.15452. Epub 2021 May 7. Br J Pharmacol. 2022. PMID: 33960398 Free PMC article. Review.
References
-
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [(accessed on 25 October 2020)]; Available online: https://coronavirus.jhu.edu/map.html.
-
- Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151. - PubMed
-
- World Health Organization Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Pdf] [(accessed on 25 October 2020)]; Available online: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mis....
-
- COVID-19 Pandemic Planning Scenarios. [(accessed on 25 October 2020)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html.
-
- Coronavirus disease 2019 (COVID-19) [(accessed on 25 October 2020)]; Available online: https://bestpractice.bmj.com/topics/en-gb/3000201.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous